Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by Vascular Endothelial Growth Factor

• Published in: Biochemical and biophysical research communications Vol. 386; no. 2; pp. 374 - 379
• Main Authors: Chen, Lei, Lu, Yin, Wu, Jia-ming, Xu, Bo, Zhang, Li-juan, Gao, Ming, Zheng, Shi-zhong, Wang, Ai-yun, Zhang, Chang-bin, Zhang, Wei-wei, Lei, Na
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 21.08.2009
• Subjects: Angiogenesis; Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Animals; Cell Movement - drug effects; Cell Proliferation - drug effects; Female; Fibroblasts - drug effects; Humans; Ligustrazine; Lung Neoplasms - prevention & control; Lung Neoplasms - secondary; Melanoma, Experimental - blood supply; Melanoma, Experimental - drug therapy; Melanoma, Experimental - pathology; Mice; Mice, Inbred C57BL; Microvessels - drug effects; Neovascularization, Pathologic - chemically induced; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - pathology; Pyrazines - pharmacology; Pyrazines - therapeutic use; Rats; Tumor metastasis; Vascular Endothelial Growth Factor A - pharmacology; VEGF; Ligustrazine; Angiogenesis; VEGF; Tumor metastasis

Angiogenesis is crucial for tumor metastasis, with many compounds that inhibit tumor metastasis acting through suppression of angiogenesis. We investigated anti-angiogenic properties of Ligustrazine in a series of in vitro and in vivo models. Ligustrazine inhibited VEGF-induced HUVECs migration and...